Skip to main content

Table 1 Characteristics of the patients at inclusion

From: Aldolase predicts subsequent myopathy occurrence in systemic sclerosis

  Patients with systemic sclerosis
(n= 137)
Age (years) 54.8 ± 12.9
Female, n (%) 125 (91.2)
Duration of SSc disease (years) 12.2 ± 12.0
Diffuse, n (%) 42 (31)
Modified Rodnan skin score 8.1 ± 6.0
Myalgia, n (%) 77 (56)
DLCO (% pred) 64 ± 17
ILD, n (%) 51 (37.1)
ATA, n (%) 37 (27)
ACA, n (%) 62 (45)
Anti U1-RNP antibody 8 (5.8)
Anti U3-RNP antibody 6 (4.3)
Anti PM-Scl antibody 5 (3.6)
Anti RNA polymerase III antibody 4 (2.9)
C-reactive protein (mg/L) 5.2 ± 7.6
Plasma aspartate transaminases (0 to 32 U/L) 23.1 ± 9.3
Plasma alanine transaminases (0 to 32 U/L) 21.5 ± 14.0
Plasma aldolase (0 to 7 U/L) 10.3 ± 7.5
Plasma creatine kinase (0 to 160 U/L) 111.1 ± 142.1
Immunosuppressive treatment, n (%) 18 (13)
  1. % of pred, percentage of predicted value; ACA, Anti-centromere antibodiy; U3-RNP, Anti U3-RNP antibody; anti-PM-Scl, anti-polymyositis-scleroderma antibody; ATA, Anti-topoisomerase I antibody; DLCO, diffusing capacity of carbon monoxide; ILD, interstitial lung disease; PM-Scl, polymyositis scleroderma; sPAP, Systolic pulmonary artery pressure assessed by echocardiogram; U1-RNP, U1-ribonucleic protein. Among 18 patients with immunosuppressive therapy, nine had corticosteroid dose less than 10 mg/day.